Acting on a resistance mutation before the scan shows progression? SERENA-6 tested exactly that.
Dr. Sarah Sammons (@drsarahsam) explains why acting on ESR1 early, before radiographic progression, is a new strategy and why it works. In the trial, switching to camizestrant at ESR1 detection prolonged progression-free survival, helping patients stay on first-line therapy longer.
Swipe through to see what it means for your practice ➡️
🎥 Watch the full conversation with Drs. Neil Iyengar (@Neil_Iyengar), Sarah Sammons & Tiffany Traina: communityhealth.media/serena-6-esr1-…
💬 Would you switch therapy on a ctDNA result alone?
Dr. Sarah Sammons (@drsarahsam) explains why acting on ESR1 early, before radiographic progression, is a new strategy and why it works. In the trial, switching to camizestrant at ESR1 detection prolonged progression-free survival, helping patients stay on first-line therapy longer.
Swipe through to see what it means for your practice ➡️
🎥 Watch the full conversation with Drs. Neil Iyengar (@Neil_Iyengar), Sarah Sammons & Tiffany Traina: communityhealth.media/serena-6-esr1-…
💬 Would you switch therapy on a ctDNA result alone?